Sildenafil in Pregnancy: A Systematic Review of Maternal Tolerance and Obstetric and Perinatal Outcomes

Fetal Diagnosis and Therapy

Volumn 41, Issue 2, 2017, Pages 81-88

  Dunn, Liam ^a   Greer, Ristan ^a   Flenady, Vicki ^a   Kumar, Sailesh ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER MOTHERS HOSPITAL   (Australia)

Author keywords

Fetal hypoxia; Fetal therapies; Placental insufficiency; Pregnancy; Sildenafil citrate

Indexed keywords

SILDENAFIL;

ADVERSE DRUG REACTION; APGAR SCORE; ARTERIAL PH; CESAREAN SECTION; CONCEPTION; CONGENITAL MALFORMATION; DYSPEPSIA; EPIGASTRIC PAIN; FEMALE; HEADACHE; HUMAN; HYPOTENSION; NEONATAL INTENSIVE CARE UNIT; NEWBORN DEATH; OUTCOME ASSESSMENT; PERINATAL OUTCOME; POSTPARTUM HEMORRHAGE; PREGNANCY OUTCOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STILLBIRTH; SYSTEMATIC REVIEW; VAGINAL DELIVERY; VISUAL DISORDER; CHEMICALLY INDUCED; NEWBORN; OBSTETRIC DELIVERY; PAIN; PREGNANCY; PREGNANCY COMPLICATION;

DELIVERY, OBSTETRIC; FEMALE; HEADACHE; HUMANS; INFANT, NEWBORN; PAIN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; SILDENAFIL CITRATE; VISION DISORDERS;

EID: 85001735581     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000453062     Document Type: Review

References (48)

1. Mehrotra N, Gupta M, Kovar A, Meibohm B: The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007; 19: 253-264.
2. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C: Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
3. Sanchez Luna M, Franco ML, Bernardo B: Therapeutic strategies in pulmonary hypertension of the newborn: where are we now? Curr Med Chem 2012; 19: 4640-4653.
4. Shah PS, Ohlsson A: Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2011:CD005494.
5. Iacovidou N, Syggelou A, Fanos V, Xanthos T: The use of sildenafil in the treatment of persistent pulmonary hypertension of the newborn: A review of the literature. Curr Pharm Des 2012; 18: 3034-3045.
6. Bédard E, Dimopoulos K, Gatzoulis MA: Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009; 30: 256-265.
7. Običan SG, Cleary KL: Pulmonary arterial hypertension in pregnancy. Semin Perinatol 2014; 38: 289-294.
8. Huang S, DeSantis ERH: Treatment of pulmonary arterial hypertension in pregnancy. Am J Health Syst Pharm 2007; 64: 1922-1926.
9. Wareing M, Myers JE, O'Hara M, Baker PN: Sildenafil citrate (viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab 2005; 90: 2550-2555.
10. Wareing M, Myers JE, O'Hara M, Kenny LC, Warren AY, Taggart MJ, Skillern L, Machin I, Baker PN: Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries. Am J Obstet Gynecol 2004; 190: 1283-1290.
11. Sher G, Fisch JD: Vaginal sildenafil (Viagra): A preliminary report of a novel method to improve uterine artery blood flow and endometrial development in patients undergoing IVF. Hum Reprod 2000; 15: 806-809.
12. Dastjerdi MV, Hosseini S, Bayani L: Sildenafil citrate and uteroplacental perfusion in fetal growth restriction. J Res Med Sci 2012; 17: 632-636.
13. El-Far M, El-Motwally AE-G, Hashem IA, Bakry N: Biochemical role of intravaginal sildenafil citrate as a novel antiabortive agent in unexplained recurrent spontaneous miscarriage: first clinical study of four case reports from Egypt. Clin Chem Lab Med 2009; 47: 1433-1438.
14. Sher G, Fisch JD: Effect of vaginal sildenafil on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development. Fertil Steril 2002; 78: 1073-1076.
15. Dilworth MR, Andersson I, Renshall LJ, Cowley E, Baker P, Greenwood S, Sibley CP, Wareing M: Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype. PLoS One 2013; 8:e77748.
16. Subbaiah M, Kumar S, Roy KK, Sharma JB, Singh N: Pregnancy outcome in women with pulmonary arterial hypertension: single-center experience from India. Arch Gynecol Obstet 2013; 288: 305-309.
17. Duarte AG, Thomas S, Safdar Z, Torres F, Pacheco LD, Feldman J: Management of pulmonary arterial hypertension during pregnancy: A retrospective, multicenter experience. Chest 2013; 143: 1330-1336.
18. Kiely DGD: Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. BJOG 2010; 117: 565-574.
19. Goland S, Tsai F, Habib M, Janmohamed M, Goodwin TM, Elkayam U: Favorable outcome of pregnancy with an elective use of epoprostenol and sildenafil in women with severe pulmonary hypertension. Cardiology 2010; 115: 205-208.
20. Ng WP, Yip WL: Successful maternal-foetal outcome using nitric oxide and sildenafil in pulmonary hypertension with atrial septal defect and HIV infection. Singapore Med J 2012; 53:e3-e5.
21. Molelekwa V, Akhter P, McKenna P, Bowen M, Walsh K: Eisenmenger's syndrome in a27 week pregnancy-management with bosentan and sildenafil. Ir Med J 2005; 98: 87-88.
22. Lacassie HJ, Germain AM, Valdes G, Fernandez MS, Allamand F, López H: Management of Eisenmenger syndrome in pregnancy with sildenafil and L-arginine. Obstet Gynecol 2004; 103: 1118-1120.
23. Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, Baker PN: A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009; 28: 369-382.
24. Trapani A Jr, Goncalves LF, Trapani TF, Vieira S, Pires M, Pires MM: Perinatal and hemodynamic evaluation of sildenafil citrate for preeclampsia treatment: A randomized controlled trial. Obstet Gynecol 2016; 128: 253-259.
25. El-Far M, Hashem IMA: Novel biopharmaceutical use of sildenafil citrate in treatment of unexplained recurrent miscarriage: first longitudinal clinical study o50 cases from Egypt. World J Pharm Pharmaceut Sci 2014; 3: 63-86.
26. von Dadelszen P, Dwinnell S, Magee LA, Carleton BC, Gruslin A, Lee B, Lim KI, Liston RM, Miller SP, Rurak D, Sherlock RL, Skoll MA, Wareing MM, Baker PN; Research into Advanced Fetal Diagnosis and Therapy (RAFT) Group: Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG 2011; 118: 624-628.
27. Panda S, Das A, Nowroz HM: Sildenafil citrate in fetal growth restriction. J Reprod Infertil 2014; 15: 168.
28. Lin T, Su Y, Shih J, Hsu H, Lee C: Resolution of high uterine artery pulsatility index and notching following sildenafil citrate treatment in a growth-restricted pregnancy. Ultrasound Obstet Gynecol 2012; 40: 609-610.
29. Trapani A, Gonçalves LF, Trapani TF, Franco MJ, Galluzzo RN, Pires MMS: Comparison between transdermal nitroglycerin and sildenafil citrate in intrauterine growth restriction: effects on uterine, umbilical and fetal middle cerebral artery pulsatility indices. Ultrasound Obstet Gynecol 2016; 48: 61-65.
30. Ganzevoort W, Alfirevic Z, von Dadelszen P, Kenny L, Papageorghiou A, van Wassenaer-Leemhuis A, Gluud C, Mol BW, Baker PN: STRIDER: Sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction-a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev 2014; 3: 23.
31. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D: The care guidelines: consensus-based clinical case reporting guideline development. Headache 2013; 53: 1541-1547.
32. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP: The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies. Prev Med 2007; 45: 247-251.
33. Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-1194.
34. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269.
35. Carey TS, Boden SD: A critical guide to case series reports. Spine 2003; 28: 1631-1634.
36. Bao Z, Zhang J, Yang D, Xu X: Analysis of high risk factors for patient death and its clinical characteristics on pregnancy associated with pulmonary arterial hypertension. Zhonghua Fu Chan Ke Za Zhi 2014; 49: 495-500.
37. Sun X, Wang K, Wang W, Li B: Clinical study on sildenafil in treatment of pregnant women with pulmonary arterial hypertension. Zhonghua Fu Chan Ke Za Zhi 2014; 49: 414-418.
38. Malinova M: Sildenafil-for treatment of preeclampsia and intrauterine growth restriction. Akush Ginekol (Sofiia) 2013; 53: 40-43.
39. Taçoy G, Ekim NN, Çengel A: Dramatic response of a patient with pregnancy induced idiopathic pulmonary arterial hypertension to sildenafil treatment. J Obstet Gynaecol Res 2010; 36: 414-417.
40. Abbott D, Comby P, Charuel C, Graepel P, Hanton G, Leblanc B, Lodola A, Longeart L, Paulus G, Peters C, Stadler J: Preclinical safety profile of sildenafil. Int J Impot Res 2004; 16: 498-504.
41. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P: Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010; 64: 240-255.
42. Gresser U, Gleiter C: Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. Eur J Med Res 2002; 7: 435-446.
43. Brock GB, McMahon CG, Chen K, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332-1336.
44. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763-771.
45. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H, Group VS: Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebocontrolled pivotal trial. Urology 2003; 61: 8-14.
46. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
47. Ford JB, Patterson JA, Seeho SKM, Roberts CL: Trends and outcomes of postpartum haemorrhage, 2003-2011. BMC Pregnancy Childbirth 2015; 15: 334.
48. Dunn L, Flenady V, Kumar S: Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): A double-blind randomised control trial. J Transl Med 2016; 14: 15.